1
|
Jones DA, Rathod KS, Williamson A, Harrington D, Andiapen M, van Eijl S, Westwood M, Antoniou S, Schilling RJ, Ahluwalia A, Mathur A. The effect of intracoronary sodium nitrite on the burden of ventricular arrhythmias following primary percutaneous coronary intervention for acute myocardial infarction. Int J Cardiol 2019; 266:1-6. [PMID: 29887423 DOI: 10.1016/j.ijcard.2018.01.029] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2017] [Revised: 01/06/2018] [Accepted: 01/08/2018] [Indexed: 12/19/2022]
Abstract
OBJECTIVE Pre-clinical evidence suggests delivery of nitric oxide (NO) through administration of inorganic nitrite suppresses arrhythmias resulting from acute ischaemia and reperfusion (I/R). To date no assessment of whether inorganic nitrite might limit reperfusion arrhythmia has occurred in man, therefore we explored the effects on I/R-induced ventricular arrhythmias in the NITRITE-AMI cohort. METHODS In the NITRITE-AMI cohort, Holter analysis was performed prior to and for 24 h after primary PCI in 80 patients who received either intra-coronary sodium nitrite (N = 40) or placebo (N = 40) during primary PCI for AMI. RESULTS Ventricular rhythm disturbance was experienced by 100% patients; however, there was no difference in the number between the groups, p = .2196. Non-sustained ventricular tachycardia (NSVT) occurred in 67.5% (27/40) of nitrite-treated patients compared to 89% (35/39) of those treated with placebo (p = .027). There was a significant reduction in both the number of runs (63%, p ≤.0001) and total beats of NSVT (64%, p = .0019) in the nitrite-treated patients compared to placebo. Post-hoc analyses demonstrate a direct correlation of occurrence of NSVT with infarct size, with the correlation stronger in the placebo versus the nitrite group initiating an independent nitrite effect (Nitrite: r = 0.110, p = .499, placebo: r = 0.527, p = .001, p for comparison: 0.004). CONCLUSION Overall no difference in ventricular rhythm disturbance was seen with intra-coronary nitrite treatment during primary PCI in STEMI patients, however nitrite treatment was associated with an important reduction in the incidence and severity of NSVT. In view of the sustained reduction of MACE seen, this effect warrants further study in a large-scale trial.
Collapse
Affiliation(s)
- Daniel A Jones
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, United Kingdom; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom.
| | - Krishnaraj S Rathod
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, United Kingdom; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Anna Williamson
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Deirdre Harrington
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Mervyn Andiapen
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Sven van Eijl
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, United Kingdom
| | - Mark Westwood
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Sotiris Antoniou
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Richard J Schilling
- Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| | - Amrita Ahluwalia
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, United Kingdom
| | - Anthony Mathur
- Centre of Clinical Pharmacology, William Harvey Research Institute, Barts & The London Medical School, Queen Mary University of London, United Kingdom; Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, United Kingdom
| |
Collapse
|
2
|
Unverzagt S, Wachsmuth L, Hirsch K, Thiele H, Buerke M, Haerting J, Werdan K, Prondzinsky R. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome. Cochrane Database Syst Rev 2014:CD009669. [PMID: 24385385 DOI: 10.1002/14651858.cd009669.pub2] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
BACKGROUND The recently published German-Austrian S3 Guideline for the treatment of infarct related cardiogenic shock (CS) revealed a lack of evidence for all recommended therapeutic measures. OBJECTIVES To determine the effects in terms of efficacy, efficiency and safety of cardiac care with inotropic agents and vasodilator strategies versus placebo or against each other for haemodynamic stabilisation following surgical treatment, interventional therapy (angioplasty, stent implantation) and conservative treatment (that is no revascularization) on mortality and morbidity in patients with acute myocardial infarction (AMI) complicated by CS or low cardiac output syndrome (LCOS). SEARCH METHODS We searched CENTRAL, MEDLINE (Ovid), EMBASE (Ovid) and ISI Web of Science, registers of ongoing trials and proceedings of conferences in January 2013. Reference lists were scanned and experts in the field were contacted to obtain further information. No language restrictions were applied. SELECTION CRITERIA Randomised controlled trials in patients with AMI complicated by CS or LCOS. DATA COLLECTION AND ANALYSIS Data collection and analysis were performed according to the published protocol. All trials were analysed individually. Hazard ratios (HRs) and odds ratios with 95% confidence intervals (CI) were extracted but not pooled because of high heterogeneity between the control group interventions. MAIN RESULTS Four eligible, very small studies were identified from a total of 4065 references. Three trials with high overall risk of bias compared levosimendan to standard treatment (enoximone or dobutamine) or placebo. Data from a total of 63 participants were included in our comparisons, 31 were treated with levosimendan and 32 served as controls. Levosimendan showed an imprecise survival benefit in comparison with enoximone based on a very small trial with 32 participants (HR 0.33; 95% CI 0.11 to 0.97). Results from the other similarly small trials were too imprecise to provide any meaningful information about the effect of levosimendan in comparison with dobutamine or placebo. Only small differences in haemodynamics, length of hospital stay and the frequency of major adverse cardiac events or adverse events overall were found between study groups.Only one small randomised controlled trial with three participants was found for vasodilator strategies (nitric oxide gas versus placebo) in AMI complicated by CS or LCOS. This study was too small to draw any conclusions on the effects on our key outcomes. AUTHORS' CONCLUSIONS At present there are no robust and convincing data to support a distinct inotropic or vasodilator drug based therapy as a superior solution to reduce mortality in haemodynamically unstable patients with CS or low cardiac output complicating AMI.
Collapse
Affiliation(s)
- Susanne Unverzagt
- Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Magdeburge Straße 8, Halle/Saale, Germany, 06097
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Chakrabarti AK, Patel SJ, Salazar RL, Gopalakrishnan L, Kumar V, Rastogi U, Singh P, Zorkun C, Gibson CM. Newer Pharmaceutical Agents for STEMI Interventions. Interv Cardiol Clin 2012; 1:429-440. [PMID: 28581961 DOI: 10.1016/j.iccl.2012.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
ST-elevation myocardial infarction (STEMI) causes 12.6% of deaths worldwide. Treatment strategies involve early revascularization by percutaneous coronary intervention and/or fibrinolytics, with adjunctive pharmacologic therapy. While antiplatelet therapy remains the cornerstone of pharmacologic management, newer antithrombotic therapies are showing benefit in the reduction of long-term thrombotic events following acute vessel occlusion. Future directions in adjunctive STEMI management include the use of hematopoietic stem cell therapy or growth factors to induce proliferation and differentiation of cardiac myocytes.
Collapse
Affiliation(s)
- Anjan K Chakrabarti
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Shalin J Patel
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Robert L Salazar
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Lakshmi Gopalakrishnan
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA; Cardiovascular Division, Department of Medicine, PERFUSE Angiographic Core Laboratories, Data Coordinating Center, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Varun Kumar
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA; Cardiovascular Division, Department of Medicine, PERFUSE Angiographic Core Laboratories, Data Coordinating Center, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Ujjwal Rastogi
- Cardiovascular Division, Department of Medicine, PERFUSE Angiographic Core Laboratories, Data Coordinating Center, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Priyamvada Singh
- Cardiovascular Division, Department of Medicine, PERFUSE Angiographic Core Laboratories, Data Coordinating Center, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA
| | - Cafer Zorkun
- Cardiovascular Division, Department of Medicine, PERFUSE Angiographic Core Laboratories, Data Coordinating Center, Beth Israel Deaconess Medical Center, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA; Division of Cardiology, Yedikule Education and Research Hospital, Istanbul, Turkey
| | - C Michael Gibson
- Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Deaconess 319, Boston, MA 02215, USA; WikiDoc Foundation (a 509 (a)(1) Charitable Organization), San Francisco, California.
| |
Collapse
|
4
|
Perez MI, Musini VM, Wright JM. Effect of early treatment with anti-hypertensive drugs on short and long-term mortality in patients with an acute cardiovascular event. Cochrane Database Syst Rev 2009:CD006743. [PMID: 19821384 DOI: 10.1002/14651858.cd006743.pub2] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
BACKGROUND Acute cardiovascular events represent a therapeutic challenge. Blood pressure lowering drugs are commonly used and recommended in the early phase of these settings. This review analyses randomized controlled trial (RCT) evidence for this approach. OBJECTIVES To determine the effect of immediate and short-term administration of anti-hypertensive drugs on all-cause mortality, total non-fatal serious adverse events (SAE) and blood pressure, in patients with an acute cardiovascular event, regardless of blood pressure at the time of enrollment. SEARCH STRATEGY MEDLINE, EMBASE, and Cochrane clinical trial register from Jan 1966 to February 2009 were searched. Reference lists of articles were also browsed. In case of missing information from retrieved articles, authors were contacted. SELECTION CRITERIA Randomized controlled trials (RCTs) comparing anti-hypertensive drug with placebo or no treatment administered to patients within 24 hours of the onset of an acute cardiovascular event. DATA COLLECTION AND ANALYSIS Two reviewers independently extracted data and assessed risk of bias. Fixed effects model with 95% confidence intervals (CI) were used. Sensitivity analyses were also conducted. MAIN RESULTS Sixty-five RCTs (N=166,206) were included, evaluating four classes of anti-hypertensive drugs: ACE inhibitors (12 trials), beta-blockers (20), calcium channel blockers (18) and nitrates (18). Acute stroke was studied in 6 trials (all involving CCBs). Acute myocardial infarction was studied in 59 trials. In the latter setting immediate nitrate treatment (within 24 hours) reduced all-cause mortality during the first 2 days (RR 0.81, 95%CI [0.74,0.89], p<0.0001). No further benefit was observed with nitrate therapy beyond this point. ACE inhibitors did not reduce mortality at 2 days (RR 0.91,95%CI [0.82, 1.00]), but did after 10 days (RR 0.93, 95%CI [0.87,0.98] p=0.01). No other blood pressure lowering drug administered as an immediate treatment or short-term treatment produced a statistical significant mortality reduction at 2, 10 or >/=30 days. There was not enough data studying acute stroke, and there were no RCTs evaluating other acute cardiovascular events. AUTHORS' CONCLUSIONS Nitrates reduce mortality (4-8 deaths prevented per 1000) at 2 days when administered within 24 hours of symptom onset of an acute myocardial infarction. No mortality benefit was seen when treatment continued beyond 48 hours. Mortality benefit of immediate treatment with ACE inhibitors post MI at 2 days did not reach statistical significance but the effect was significant at 10 days (2-4 deaths prevented per 1000). There is good evidence for lack of a mortality benefit with immediate or short-term treatment with beta-blockers and calcium channel blockers for acute myocardial infarction.
Collapse
Affiliation(s)
- Marco I Perez
- Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, 2176 Health Science Mall, Vancouver, BC, Canada, V6T 1Z3
| | | | | |
Collapse
|
5
|
The CORONIS Trial. International study of caesarean section surgical techniques: a randomised fractional, factorial trial. BMC Pregnancy Childbirth 2007; 7:24. [PMID: 18336721 PMCID: PMC2217555 DOI: 10.1186/1471-2393-7-24] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2007] [Accepted: 10/22/2007] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Caesarean section is one of the most commonly performed operations on women throughout the world. Rates have increased in recent years - about 20-25% in many developed countries. Rates in other parts of the world vary widely.A variety of surgical techniques for all elements of the caesarean section operation are in use. Many have not yet been rigorously evaluated in randomised controlled trials, and it is not known whether any are associated with better outcomes for women and babies. Because huge numbers of women undergo caesarean section, even small differences in post-operative morbidity rates between techniques could translate into improved health for substantial numbers of women, and significant cost savings. DESIGN CORONIS is a multicentre, fractional, factorial randomised controlled trial and will be conducted in centres in Argentina, Ghana, India, Kenya, Pakistan and Sudan. Women are eligible if they are undergoing their first or second caesarean section through a transverse abdominal incision. Five comparisons will be carried out in one trial, using a 2 x 2 x 2 x 2 x 2 fractional factorial design. This design has rarely been used, but is appropriate for the evaluation of several procedures which will be used together in clinical practice. The interventions are:* Blunt versus sharp abdominal entry* Exteriorisation of the uterus for repair versus intra-abdominal repair* Single versus double layer closure of the uterus* Closure versus non-closure of the peritoneum (pelvic and parietal)* Chromic catgut versus Polyglactin-910 for uterine repairThe primary outcome is death or maternal infectious morbidity (one or more of the following: antibiotic use for maternal febrile morbidity during postnatal hospital stay, antibiotic use for endometritis, wound infection or peritonitis) or further operative procedures; or blood transfusion. The sample size required is 15,000 women in total; at least 7,586 women in each comparison. DISCUSSION Improvements in health from optimising caesarean section techniques are likely to be more significant in developing countries, because the rates of postoperative morbidity in these countries tend to be higher. More women could therefore benefit from improvements in techniques. TRIAL REGISTRATION The CORONIS Trial is registered in the Current Controlled Trials registry. ISCRTN31089967.
Collapse
Affiliation(s)
-
- National Perinatal Epidemiology Unit, University of Oxford, Old Road Campus, Oxford, OX3 7LF, UK .
| |
Collapse
|
6
|
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O’Connor CM, O’Gara PT, Oparil S. REPRINT Treatment of Hypertension in the Prevention and Management of Ischemic Heart Disease. Hypertension 2007. [DOI: 10.1161/hypertensionaha.107.183885] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
7
|
Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL, Kaplan NM, O'Connor CM, O'Gara PT, Oparil S. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 2007; 115:2761-88. [PMID: 17502569 DOI: 10.1161/circulationaha.107.183885] [Citation(s) in RCA: 500] [Impact Index Per Article: 29.4] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
8
|
Abstract
BACKGROUND Mortality and morbidity from acute myocardial infarction (AMI) remain high. Intravenous magnesium started early after the onset of AMI is thought to be a promising adjuvant treatment. Conflicting results from earlier trials and meta-analyses warrant a systematic review of available evidence. OBJECTIVES To examine the effect of intravenous magnesium versus placebo on early mortality and morbidity. SEARCH STRATEGY We searched CENTRAL (The Cochrane Library Issue 3, 2006), MEDLINE (January 1966 to June 2006) and EMBASE (January 1980 to June 2006), and the Chinese Biomedical Disk (CBM disk) (January 1978 to June 2006). Some core Chinese medical journals relevant to the cardiovascular field were hand searched from their starting date to the first-half year of 2006. SELECTION CRITERIA All randomized controlled trials that compared intravenous magnesium with placebo in the presence or absence of fibrinolytic therapy in addition to routine treatment were eligible if they reported mortality and morbidity within 35 days of AMI onset. DATA COLLECTION AND ANALYSIS Two reviewers independently assessed the trial quality and extracted data using a standard form. Odds ratio (OR) were used to pool the effect if appropriate. Where heterogeneity of effects was found, clinical and methodological sources of this were explored. MAIN RESULTS For early mortality where there was evidence of heterogeneity, a fixed-effect meta-analysis showed no difference between magnesium and placebo groups (OR 0.99, 95%CI 0.94 to 1.04), while a random-effects meta-analysis showed a significant reduction comparing magnesium with placebo (OR 0.66, 95% CI 0.53 to 0.82). Stratification by timing of treatment (< 6 hrs, 6+ hrs) reduced heterogeneity, and in both fixed-effect and random-effects models no significant effect of magnesium was found. In stratified analyses, early mortality was reduced for patients not treated with thrombolysis (OR=0.73, 95% CI 0.56 to 0.94 by random-effects model) and for those treated with less than 75 mmol of magnesium (OR=0.59, 95% CI 0.49 to 0.70) in the magnesium compared with placebo groups.Meta-analysis for the secondary outcomes where there was no evidence of heterogeneity showed reductions in the odds of ventricular fibrillation (OR=0.88, 95% CI 0.81 to 0.96), but increases in the odds of profound hypotension (OR=1.13, 95% CI 1.09 to 1.19) and bradycardia (OR=1.49, 95% CI 1.26 to 1.77) comparing magnesium with placebo. No difference was observed for heart block (OR=1.05, 95% CI 0.97-1.14). For those outcomes where there was evidence of heterogeneity, meta-analysis with both fixed-effect and random-effects models showed that magnesium could decrease ventricular tachycardia (OR=0.45, 95% CI 0.31 to 0.66 by fixed-effect model; OR=0.40, 95% CI 0.19 to 0.84 by random-effects model) and severe arrhythmia needing treatment or Lown 2-5 (OR=0.72, 95% CI 0.60 to 0.85 by fixed-effect model; OR=0.51, 95% CI 0.33 to 0.79 by random-effects model) compared with placebo. There was no difference on the effect of cardiogenic shock between the two groups. AUTHORS' CONCLUSIONS Owing to the likelihood of publication bias and marked heterogeneity of treatment effects, it is essential that the findings are interpreted cautiously. From the evidence reviewed here, we consider that: (1) it is unlikely that magnesium is beneficial in reducing mortality both in patients treated early and in patients treated late, and in patients already receiving thrombolytic therapy; (2) it is unlikely that magnesium will reduce mortality when used at high dose (>=75 mmol); (3) magnesium treatment may reduce the incidence of ventricular fibrillation, ventricular tachycardia, severe arrhythmia needing treatment or Lown 2-5, but it may increase the incidence of profound hypotension, bradycardia and flushing; and (4) the areas of uncertainty regarding the effect of magnesium on mortality remain the effect of low dose treatment (< 75 mmol) and in patients not treated with thrombolysis.
Collapse
Affiliation(s)
- J Li
- West China Hospital,Sichuan University, Chinese Cochrane Centre, Chengdu, Sichuan, China, 610041.
| | | | | | | |
Collapse
|
9
|
Rhodes JF, Lane GK, Tuzcu EM, Latson LA. Invasive echocardiography: the use of catheter imaging by the interventional cardiologist. Catheter Cardiovasc Interv 2003; 59:277-90. [PMID: 12772260 DOI: 10.1002/ccd.10453] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Ultrasound imaging is frequently used for diagnostic purposes or guidance during procedures in the pediatric and congenital cardiac catheterization laboratory. As new imaging modalities emerged, many interventional cardiologists rather than noninvasive specialists are now performing the ultrasound imaging as part of the catheterization. The focus of this discussion will be to detail the technique and application of echocardiography by the interventional cardiologist.
Collapse
Affiliation(s)
- John F Rhodes
- The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
| | | | | | | |
Collapse
|
10
|
Current and Practical Management of Acute Myocardial Infarction. J Thromb Thrombolysis 2000; 4:375-396. [PMID: 10639644 DOI: 10.1023/a:1008801500912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
11
|
Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation 1998; 97:2202-12. [PMID: 9631869 DOI: 10.1161/01.cir.97.22.2202] [Citation(s) in RCA: 411] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Several large-scale trials have demonstrated improved survival with ACE-inhibitor therapy started during acute myocardial infarction. A systematic overview was conducted to resolve uncertainties regarding time of initiation, time course of effect, and identification of patients in whom the benefits or the risks may be greater. METHODS AND RESULTS This overview aimed to include individual data from all randomized trials involving more than 1000 patients in which ACE-inhibitor treatment was started in the acute phase (0 to 36 hours) of myocardial infarction and continued for a short time (4 to 6 weeks). Data were available for 98,496 patients from 4 eligible trials, and the results were consistent among the trials. Thirty-day mortality was 7.1% among patients allocated to ACE inhibitors and 7.6% among control subjects, corresponding to a 7% (SD, 2%) proportional reduction (95% CI, 2% to 11%; 2P<0.004). This represented avoidance of approximately 5 (SD, 2) deaths per 1000 patients, with most of the benefit observed within the first week. The proportional benefit was similar in patients at different underlying risk. The absolute benefit was particularly large in some high-risk groups (ie, Killip class 2 to 3, heart rate > or = 100 bpm at entry) and in anterior MI. ACE-inhibitor therapy also reduced the incidence of nonfatal cardiac failure (14.6% versus 15.2%, 2P=0.01) but was associated with an excess of persistent hypotension (17.6% versus 9.3%, 2P<0.01) and renal dysfunction (1.3% versus 0.6%, 2P<0.01). CONCLUSIONS These results support the use of ACE inhibitors early in the treatment of acute MI, either to a wide range of patients or selectively in patients with anterior MI and in those at increased risk of death.
Collapse
|
12
|
Borghi C, Ambrosioni E. Clinical aspects of ACE inhibition in patients with acute myocardial infarction. Cardiovasc Drugs Ther 1996; 10:519-25. [PMID: 8950065 DOI: 10.1007/bf00050991] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The purpose of the present article was to review the current evidence on the use of angiotensin-converting enzyme (ACE) inhibitors in acute myocardial infarction (MI). This article is based on published information as well as on our personal experience derived from an extensive analysis of the SMILE study. All the randomized trials have been included irrespective of the primary endpoint, and the results are presented in terms of either hemodynamic or clinical benefit. Short- and long-term treatment with ACE inhibitors in patients with acute MI results in a significant reduction in mortality, which is more evident in high risk patients (i.e., patients with left ventricular dysfunction, congestive heart failure on admission, or anterior myocardial infarction). Development and progression of congestive heart failure after myocardial infarction was significantly reduced by ACE inhibition, which also reduced the rate of reinfarction, the need for revascularization procedures, as well as the occurrence of ventricular arrhythmias, probably through a mechanism involving some drug-dependent effects. In conclusion, the available data strongly support a wide benefit associated with the use of ACE inhibitors in patients with high-risk acute MI.
Collapse
Affiliation(s)
- C Borghi
- Department of Medicine, University of Bologna, Italy
| | | |
Collapse
|
13
|
Abstract
The use of ACE inhibitors in patients with myocardial infarction (MI) has been the subject of several studies conducted during recent years. These studies have demonstrated the capacity of these agents to improve both survival and morbidity of patients with MI. However, the use of ACE inhibitors in patients with MI has been shown to reduce blood pressure (BP) and so could jeopardise the ischaemic myocardium. A significant reduction in systemic BP has been demonstrated by all the studies of ACE inhibitors in patients with MI, but no relationship has been found between the occurrence of hypotension and a worse clinical outcome. An increased risk of death has been observed exclusively in association with severe and sudden hypotension, the occurrence of which can be largely prevented by the administration of the ACE inhibitor according to an increasing dose-titration scheme. Conversely, a certain degree of long term BP reduction could result in some beneficial effect in patients with MI and contribute to the lower incidence of re-infarction observed in patients with acute MI undergoing long term treatment with captopril. Since the renin-angiotensin system is strictly related to kidney function, its blockade by an ACE inhibitor could result in some degree of renal dysfunction, particularly in patients with MI and impaired ventricular function. The available results from large-scale studies suggest that abnormalities in kidney function (namely an increase in serum creatinine) are observed in 0.9 to 2.4% of patients with MI who, nevertheless, experience some benefit from treatment with ACE inhibitors. Interestingly, the administration of ACE inhibitors does not seem to further compromise severely impaired renal function, and may also represent a useful tool for the treatment of patients with renal dysfunction associated with MI. The use of ACE inhibitors in patients with MI is associated with a satisfactory clinical and laboratory safety profile. The occurrence of significant adverse effects seems to be very low and mainly attributable to a rather modest prevalence of cough (2.4 to 6.8%). Discontinuation of treatment because of biochemical and haematological abnormalities has been observed in less than 1% of treated patients. Thus, the beneficial effects of ACE inhibitor treatment seem to outweigh safety concerns, thereby reinforcing the role of ACE inhibition as a suitable therapeutic strategy in the treatment of patients with MI.
Collapse
Affiliation(s)
- C Borghi
- Department of Medicine, University of Bologna, Italy
| | | |
Collapse
|
14
|
Selig MB. Early management of acute myocardial infarction: thrombolysis, angioplasty, and adjunctive therapies. Am J Emerg Med 1996; 14:209-17. [PMID: 8924149 DOI: 10.1016/s0735-6757(96)90135-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Early identification and treatment, including administration of intravenous thrombolytics, coronary angioplasty, and adjunctive therapies, has been shown to benefit patients who present with acute myocardial infarction. However, only a small percentage of these patients receive such therapies because of late presentation, associated risks, and controversies around certain myocardial infarct subsets. The logistics involved in carrying out these treatments have resulted in unnecessary prehospital and in-hospital delays. These issues make essential the availability of a streamlined protocol that should be updated at regular intervals to ensure that these time-dependent therapies are more routinely and rapidly utilized. This article discusses these topics in conceptual format and provides a ready-to-use protocol.
Collapse
Affiliation(s)
- M B Selig
- Division of Cardiology, Muhlenberg Hospital Center, Bethlehem, PA 18017-7474, USA
| |
Collapse
|
15
|
|
16
|
Seelig MS. ISIS 4: clinical controversy regarding magnesium infusion, thrombolytic therapy, and acute myocardial infarction. Nutr Rev 1995; 53:261-4. [PMID: 8577409 DOI: 10.1111/j.1753-4887.1995.tb05483.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Abstract
Magnesium (Mg) infusions over 24 hours were given to patients with suspected acute myocardial infarction (AMI) at least 2 hours after thrombolysis. Patients showed no benefit and even some increased risk in contrast to reduction in mortality obtained by Mg therapy in smaller trials. Results of all of the studies were pooled and statistically analyzed, according to a fixed-effects model that is inappropriate for studies of different protocols. The panel concluded that further study of Mg in AMI is not needed. This conclusion has been questioned.
Collapse
Affiliation(s)
- M S Seelig
- Department of Nutrition, School of Public Health, University of North Carolina, Chapel Hill, USA
| |
Collapse
|
17
|
Nony P, Boissel JP, Lièvre M, Cucherat M, Haugh MC, Dayoub G. [Introduction to meta-analytic methodology]. Rev Med Interne 1995; 16:536-46. [PMID: 7569424 DOI: 10.1016/0248-8663(96)80751-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
General considerations about meta-analysis and the different steps of this technique are successively discussed: definition of the main objective, identification of the outcome, description of the retrieval and selection of trials, description of the statistical analysis and interpretation of the results. Advantages and drawbacks of the meta-analytical technique are then described: 1) scientific approach, possible quantification of the therapeutic effect, increase of the power of a future clinical trial, synthesis of contradicting results, assessment of the homogeneity, subgroup analysis, analysis of sensibility, scientific collaboration, help for therapeutic information. 2) retrospective approach, inconsistency among trials, potential biases, persistence of some unsolved methodological problems, difficulties for a critical reading and for the interpretation of conclusions. In addition, some examples of published meta-analyses are given to illustrate the advantages and limits mentioned above.
Collapse
Affiliation(s)
- P Nony
- Service de pharmacologie clinique, hôpital Cardiologique, Lyon, France
| | | | | | | | | | | |
Collapse
|
18
|
Yim JM, Hoon TJ, Bittar N, Bauman JL, Brown EJ, Celestin C, Phillips BG, Vlasses PH. Angiotensin-converting enzyme inhibitor use in survivors of acute myocardial infarction. Am J Cardiol 1995; 75:1184-6. [PMID: 7762512 DOI: 10.1016/s0002-9149(99)80757-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Affiliation(s)
- J M Yim
- University Hospital Consortium, Oak Brook, Illinois 60521-1890, USA
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Coronary flow and thus myocardial perfusion is regulated by myogenic, metabolic, humoral and neuro-hormonal factors which closely interact with local autacoids released from the endothelial lining of the coronary bed. In a number of disease states an impaired synthesis and release of autacoids decisively limit the overall capacity of coronary regulation and adaptation of myocardial perfusion to increased metabolic demands. The important factors for these control mechanisms are analyzed and reviewed in this article.
Collapse
Affiliation(s)
- E Bassenge
- Institut für Angewandte Physiologie Universität Freiburg, Germany
| |
Collapse
|
20
|
|
21
|
|